hotspot -WSS

hotspot

author：entertainment 2025-09-27 12:54:34 - browse：59

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Pharma showers House GOP doctor with campaign cash

WSS

Late stage cancers on the rise after pandemic delayed screenings

Criminal prosecution for violating HIPAA: an emerging threat

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Wearables generate powerful data but its not useful to doctors, yet

focus

hotspot

focus

Drug repurposing or repositioning? The language matters

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Dobbs anniversary: the lost opportunity of abortion as health care

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Hepatitis C has a cure — but many Americans still lack access to it

Group behind ProMed defends move to subscription

Medical records are filled with copy

Group behind ProMed defends move to subscription

Medicare details structure of new drug price negotiation program

When prostate cancer spreads, where it goes matters

focus

FDA approves Sage Therapeutics’ rapid

Case highlights the risks of experimental stem cell therapy

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Helping hospitals and community health centers plan for resilience

Wikipedia

hotspot

hotspot

hotspot